Factors Associated With Detection and Survival of T1 Hepatocellular Carcinoma in the United States: National Cancer Database Analysis.

BACKGROUND It remains unknown to what extent hepatocellular carcinomas (HCCs) are detected very early (T1 stage; ie, unifocal <2 cm) in the United States. The aim of this study was to investigate the trends and factors associated with very early detection of HCC and resultant outcomes. METHODS Patients with HCC diagnosed from 2004 through 2014 were identified from the National Cancer Database. Logistic regression was used to identify factors associated with T1 HCC detection, and Cox proportional hazard analyses identified factors associated with overall survival among patients with T1 HCC. RESULTS Of 110,182 eligible patients, the proportion with T1 HCC increased from 2.6% in 2004 to 6.8% in 2014 (P<.01). The strongest correlate of T1 HCC detection was receipt of care at an academic institution (odds ratio, 3.51; 95% CI, 2.31-5.34). Older age, lack of insurance, high Model for End-Stage Liver Disease (MELD) score, high alpha-fetoprotein, increased Charlson-Deyo comorbidity score, and nonsurgical treatment were associated with increased mortality, and care at an academic center (hazard ratio [HR], 0.27; 95% CI, 0.15-0.48) was associated with reduced mortality in patients with T1 HCC. Liver transplantation (HR, 0.27; 95% CI, 0.20-0.37) and surgical resection (HR, 0.67; 95% CI, 0.48-0.93) were independently associated with improved survival compared with ablation. This is the first study to examine the trend of T1 HCC using the National Cancer Database, which covers approximately 70% of all cancer diagnoses in the United States, using robust statistical analyses. Limitations of the study include a retrospective study design using administrative data and some pertinent data that were not available. CONCLUSIONS Despite increases over time, <10% of HCCs are detected at T1 stage. The strongest correlates of survival among patients with T1 HCC are receiving care at an academic institution and surgical treatment.

[1]  J. An,et al.  Magnetic Resonance Imaging Is Cost‐Effective for Hepatocellular Carcinoma Surveillance in High‐Risk Patients With Cirrhosis , 2019, Hepatology.

[2]  J. Yang,et al.  Detect or not to detect very early stage hepatocellular carcinoma? The western perspective , 2019, Clinical and molecular hepatology.

[3]  J. Marrero,et al.  Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  J. Uhlig,et al.  Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database , 2018, European Radiology.

[5]  G. Gores,et al.  GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[6]  S. Curley,et al.  Impact of the Treating Hospital on Care Outcomes for Hepatocellular Carcinoma , 2018, Hepatology.

[7]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[8]  J. Marrero,et al.  Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. , 2018, Gastroenterology.

[9]  Chia-Yang Hsu,et al.  Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation , 2018, Scientific Reports.

[10]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[11]  C. Sirlin,et al.  Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta‐analysis , 2018, Hepatology.

[12]  M. Kudo.  Management of Hepatocellular Carcinoma in Japan as a World-Leading Model , 2017, Liver Cancer.

[13]  D. Goldberg,et al.  Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. , 2017, Gastroenterology.

[14]  G. Gores,et al.  Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  Neil Mehta,et al.  Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant , 2017, JAMA oncology.

[16]  J. Byun,et al.  MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma , 2017, JAMA oncology.

[17]  D. Palma.  National Cancer Data Base: An Important Research Tool, but Not Population-Based. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Meyer,et al.  A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[19]  M. Manns,et al.  Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  J. Marrero,et al.  Hospital Volume and Survival After Hepatocellular Carcinoma Diagnosis , 2016, The American Journal of Gastroenterology.

[21]  J. Roberts,et al.  Intention to treat outcome of T1 hepatocellular carcinoma with the “wait and not ablate” approach until meeting T2 criteria for liver transplant listing , 2016, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Kawasaki,et al.  Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[24]  Amit G. Singal,et al.  Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis , 2014, PLoS medicine.

[25]  L. Bolondi,et al.  Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. , 2013, Journal of hepatology.

[26]  M. Pompili,et al.  Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. , 2013, Journal of hepatology.

[27]  L. Mariani,et al.  Resection of hepatocellular cancer ≤2 cm: Results from two Western centers , 2013, Hepatology.

[28]  F. Xia,et al.  A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. , 2012, Journal of hepatology.

[29]  T. Therneau,et al.  Model to estimate survival in ambulatory patients with hepatocellular carcinoma , 2012, Hepatology.

[30]  T. Therneau,et al.  Factors that affect risk for hepatocellular carcinoma and effects of surveillance. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  T. Roskams.  Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. , 2011, Clinics in liver disease.

[32]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[33]  Yong Zeng,et al.  A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria , 2010, Annals of surgery.

[34]  J. Chung,et al.  Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: A Markov model analysis , 2010, Hepatology.

[35]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[36]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[37]  N. Tabibian.  Hepatocellular carcinoma in the United States. , 1988, American family physician.

[38]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[39]  A. Singal,et al.  Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices , 2017 .

[40]  M. Choi,et al.  Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. , 2013, Journal of hepatology.

[41]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.